Treatment
Mercaptopurine clinical trials
We’re tracking 30 recruiting studies that include Mercaptopurine, each written for real people, not researchers, below.
Recruiting studies
- NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Birmingham, AlabamaAges 18–39 - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT02877303RecruitingPhase 2
Frontline drug treatment for newly diagnosed B-cell leukemia
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
Houston, TexasAges 14 years+ - NCT00501826RecruitingPhase 2
Check nelarabine plus chemotherapy for T-cell blood cancers
This trial tests a combination of chemotherapy with nelarabine in people with T-cell acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma. It may help by improving remission in newly diagnosed or certain previously treated patients whose disease did not respond after one initial treatment.
Houston, TexasAges Any age - NCT07431060Recruiting
Modified LCH treatment with or without Luvometinib for children
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
ChengduAges birth–18 years - NCT03571321RecruitingPhase 1
Ruxolitinib plus chemotherapy for Ph-like B-ALL
This early-phase study tests whether adding ruxolitinib (a targeted medicine) to standard chemotherapy improves outcomes in adolescents and young adults with newly diagnosed Ph-like B-precursor acute lymphoblastic leukemia (ALL). It targets specific genetic features (“JAK-targetable signature”) thought to make the leukemia more responsive to JAK-blocking treatment.
Chicago, IllinoisAges 18–39
Common questions
- Are there clinical trials studying Mercaptopurine?
- Yes. Clin2 currently lists 30 recruiting studies that include Mercaptopurine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Mercaptopurine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Mercaptopurine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Mercaptopurine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.